Home
    Disclaimer
    LSD molecular structure

    LSD Stats & Data

    L Cid Gel Lucy Acid lsd-25
    NPS DataHub
    MW473.53
    FormulaC24H31N3O7
    CAS17676-08-3
    IUPAC9,10-Didehydro-N,N-diethyl-6-methyl-ergoline-8-β-carboxamide
    SMILESCCN(CC)C(=O)C1CN(C)C2Cc3cnc4cccc(c34)C2=C1.O=C([O-])C(O)C(O)C(=O)[O-].[H+].[H+]
    InChIKeyHQMPRARIZOUKRO-KEZWHQCISA-N
    2020/5.2 Δ9 10-Ergolene; 2021/5.2 Δ9 10-Ergolene; 2022/5.2 Δ9 10-Ergolene
    Chemical Class Lysergamide
    Psychoactive Class Psychedelic

    Pharmacology

    DrugBank
    Half-life 3 hours State Solid Absorption Rapidly absorbed. Metabolism Hepatic.

    Description

    Debate continues over the nature and causes of chronic flashbacks. Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action of LSD on brain chemistry, and varies according to the susceptibility of the individual to the disorder. Many emotionally intense experiences can lead to flashbacks when a person is reminded acutely of the original experience. However, not all published case reports of chronic flashbacks appear to describe an anxious hyper-vigilant state reminiscent of post-traumatic stress disorder.

    Mechanism of Action

    LSD's mechanism of action is pleiotropic, primarily mediated by the serotonergic system in the Dorsal Raphe, binding the 5-HT2A receptor as a partial agonist and 5-HT1A as an agonist. LSD also modulates the Ventral Tegmental Area, at higher doses, by stimulating dopamine D₂, Trace Amine Associate receptor 1 (TAAR₁) and 5-HT2A. More studies clarifying the mechanism of action of the psychotic-like symptoms or psychosis induced by LSD in humans are needed. LSD's effects are mediated by a pleiotropic mechanism involving serotonergic, dopaminergic, and glutamatergic neurotransmission. Thus, the LSD-induced psychosis is a useful model to test the therapeutic efficacy of potential novel antipsychotic drugs, particularly drugs with dual serotonergic and dopaminergic (DA) mechanism or acting on TAAR₁ receptors.

    Toxicity

    Estimates for the lethal dosage (LD50) of LSD range from 200 µg/kg to more than 1 mg/kg of human body mass, though most sources report that there are no known human cases of such an overdose.

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (partial)
    5-HT2C receptor agonist (partial)
    5-HT1A receptor agonist (partial)
    5-HT2B receptor agonist (partial)
    5-HT6 receptor agonist
    Dopamine D2 receptor agonist

    Receptor Binding

    5-hydroxytryptamine receptor 1A inhibitor
    5-hydroxytryptamine receptor 2A inhibitor
    5-hydroxytryptamine receptor 2B agonist

    History & Culture

    1938–1943

    LSD was first synthesized on November 16, 1938, by Swiss chemist Albert Hofmann while working at Sandoz Laboratories in Basel, Switzerland. The compound emerged from a research program investigating potentially useful derivatives of ergot, a fungus that grows on rye and other grains. LSD was the twenty-fifth lysergamide derivative Hofmann synthesized from lysergic acid, which explains the designation LSD-25 (from the German "Lysergsäure-diethylamid"). The psychoactive properties of LSD remained unknown for five years until April 16, 1943, when Hofmann unintentionally ingested an unknown quantity of the substance, possibly through skin absorption. Three days later, on April 19, 1943, Hofmann conducted the first intentional self-experiment, ingesting 250 micrograms in the belief that this would produce only a threshold effect based on the typical potency of other ergot alkaloids. The effects proved far more potent than anticipated. After experiencing the onset of powerful alterations in consciousness, Hofmann rode his bicycle home—an event now commemorated annually as "Bicycle Day" among psychedelic enthusiasts. He later described experiencing unprecedented colors and kaleidoscopic, fantastic images that surged behind his closed eyes, alternating and rearranging themselves in constant flux.

    1947–1965

    In 1947, Sandoz introduced LSD to the medical community under the trade name Delysid, marketing it as an experimental tool for psychiatric applications. Two primary therapeutic models emerged: the "model-psychosis" approach, which used LSD to induce temporary psychotic-like states in healthy individuals for research purposes, and psycholytic or psychedelic therapy, which employed the substance to enhance psychotherapeutic treatments. The compound generated extraordinary interest within psychiatry during the 1950s and early 1960s. Within fifteen years of its introduction, research on LSD and related hallucinogens produced over 1,000 scientific papers, and the substance was prescribed to more than 40,000 patients. Psychiatrist Humphry Osmond pioneered applications for treating alcoholism with promising results, and the substance was reportedly tried in every type of mental disorder by 1960. Osmond also coined the term "psychedelic" (meaning "mind manifesting") to describe LSD and similar compounds, replacing the earlier "psychotomimetic" model which theorized the substance mimicked schizophrenia. The Sandoz patents on LSD expired in 1963, at which point the Czech company Spofa began production. Sandoz ceased production and distribution in 1965.

    1950–1973

    During the 1950s, the U.S. Central Intelligence Agency initiated a research program code-named Project MKUltra to investigate LSD's potential applications in mind control and chemical warfare. The CIA reportedly purchased the entire world supply of LSD for $240,000 and distributed it through front organizations to American hospitals, clinics, prisons, and research centers. The experiments involved administering LSD to CIA employees, military personnel, doctors, prostitutes, mentally ill patients, and members of the general public—frequently without their knowledge or consent. The most well-known example, Operation Midnight Climax, involved covertly dosing unwitting individuals to observe their reactions. These experiments resulted in at least one death. The U.S. Army Chemical Corps also evaluated LSD as a potential non-lethal incapacitant in the Edgewood Arsenal human experiments.

    1960–1969

    By the mid-1960s, LSD had become central to the youth counterculture, particularly in San Francisco's Haight-Ashbury neighborhood and in London. Several prominent intellectuals, including Aldous Huxley, Timothy Leary, Al Hubbard, and Alan Watts, began advocating for the mass consumption of LSD, profoundly influencing the thinking of a new generation. In 1966, Timothy Leary established the League for Spiritual Discovery with LSD as its sacrament. The first major underground LSD production operation was established by Owsley Stanley. Around this time, the Merry Pranksters, associated with novelist Ken Kesey, organized the Acid Tests—events featuring LSD consumption accompanied by light shows and improvised music. Their cross-country journeys in a psychedelically-decorated bus and interactions with major figures of the beat movement were later documented in Tom Wolfe's "The Electric Kool-Aid Acid Test" (1968). In January 1966, brothers Ron and Jay Thelin opened the Psychedelic Shop in Haight-Ashbury to promote safe use of LSD, helping establish the neighborhood as the epicenter of hippie culture. They organized the Love Pageant Rally in Golden Gate Park in October 1966 to protest California's impending ban on the substance. A parallel movement developed in London, led by British academic Michael Hollingshead, who had first experienced LSD in America in 1961. After interactions with Huxley, Leary, and Richard Alpert, Hollingshead returned to the UK in 1965 and founded the World Psychedelic Center in Chelsea, London.

    1968–1993

    On October 24, 1968, possession of LSD was made illegal in the United States. The counterculture's embrace of the substance had provoked widespread controversy and backlash in American society, leading to aggressive measures under the Nixon administration's war on drugs. Research was unceremoniously halted, and psychedelic study was driven underground. The last FDA-approved study of LSD in patients concluded in 1980, although a study in healthy volunteers was conducted in the late 1980s. Legally approved and regulated psychiatric use of LSD continued in Switzerland until 1993. The substance was placed under Schedule I of the 1971 United Nations Convention on Psychotropic Substances, establishing international prohibition.

    2000–present

    Following decades of institutional suppression, scientific research involving LSD has undergone a significant revival as part of the broader "psychedelic renaissance." The substance is currently being investigated for treatment applications including alcoholism, substance addiction, cluster headache, autism, and anxiety associated with terminal illness. In 2024, the U.S. Food and Drug Administration designated a form of LSD (MM120) as a breakthrough therapy for generalized anxiety disorder, marking a significant shift in regulatory attitudes toward the substance.

    The influence of LSD on art and music became pronounced during the 1960s. San Francisco-based visual artists such as Rick Griffin, Victor Moscoso, and Wes Wilson contributed psychedelic poster and album art to the movement. A distinct visual art style emerged, inspired by the perceptual effects and hallucinatory experiences associated with the substance. Blotter art developed as a unique art form following LSD's prohibition, with decorative graphics printed on perforated sheets of absorbent paper infused with liquid LSD. This practice originated in the early 1970s, sometimes serving to identify the dose, maker, or batch. More than 350 blotter paper designs have been documented since 1975, and entire collections have been exhibited in galleries and museums. Musically, LSD profoundly shaped the development of psychedelic rock through the Acid Tests and performances by bands like the Grateful Dead, Jefferson Airplane, and Big Brother and the Holding Company. The Grateful Dead became central to a culture of devoted followers known as "Deadheads," with their music heavily influenced by the substance. Psychedelic music of the era sought to replicate the LSD experience through exotic instrumentation, electric guitars with effects pedals, and elaborate studio techniques including sitars, tablas, backward tapes, panning, and phasing. In the United Kingdom, Michael Hollingshead introduced LSD to various artists and musicians including Storm Thorgerson, Donovan, Keith Richards, and members of the Beatles. Despite the substance's illegal status from 1966, it was widely used by groups including the Beatles, the Rolling Stones, and the Moody Blues, influencing works such as "Sgt. Pepper's Lonely Hearts Club Band" and Cream's "Disraeli Gears."

    Subjective Effect Notes

    cognitive: In comparison to other psychedelics such as Psilocin, LSA and Ayahuasca, LSD is significantly more stimulating and fast paced in terms of the specific style of thought stream which it produces and contains a large number of potential effects.

    Effect Profile

    Curated + 3,201 Reports
    Psychedelic 8.0

    Strong headspace and visuals with moderate auditory effects, mild body load

    Visual Intensity×3
    8103.4 9/24
    Headspace Depth×3
    99.62.9 6/24
    Auditory Effects×1
    7100.9 6/24
    Body Load / Somatic Effects×1
    44.63.6 5/24
    Catalog Erowid BlueLight

    User Experiences

    Headspace "I could have multiple streams of thought / conversations going on at the same time and there was no confusion." Effect Index
    Visuals "Patterns began to appear in the sky before me and form out of the sunlight reflecting off the water." Effect Index
    Auditory Effects "Eventually, the lines become cathartic- through a visual-auditory synesthesia I can hear each line scream as I forcefully drag them on the page." Effect Index

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral
    19 minutes - 1.5 hours
    45 minutes - 1.5 hours
    3-5 hours
    3-5 hours
    12-48 hours
    Total: 6.5-13 hours
    Sublingual
    15-45 minutes
    30 minutes - 1.0 hours
    3-5 hours
    3-5 hours
    12-48 hours
    Total: 9-14 hours

    Empirical Duration

    Erowid Reports
    Onset Come Up Peak Offset
    Oral (180 reports)
    Sublingual (31 reports)

    Community Effects

    TripSit
    Positive
    euphoria visual enhancement introspection creativity music enhancement color enhancement
    Negative
    anxiety paranoia confusion insomnia

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Cross-Tolerances

    Psilocybin
    80% ●○○
    Psilocin
    80% ●○○
    Mescaline
    60% ●○○
    DMT
    80% ●○○
    5-MeO-DMT
    80% ●○○
    2C-B
    60% ●○○
    2C-E
    60% ●○○
    2C-I
    60% ●○○

    Experience Report Analysis

    Erowid BlueLight
    2,192 Reports
    1990–2025 Date Range
    950 With Age Data
    33 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 2,242 experience reports (2,192 Erowid + 1,009 Bluelight)

    2,242 Reports
    128 Effects Detected
    63 Positive
    44 Adverse
    21 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 63

    Color Enhancement 50.3% 85%
    Music Enhancement 49.6% 85%
    Joy 42.0% 84%
    Empathy 39.1% 80%
    Stimulation 38.7% 75%
    Euphoria 36.9% 87%
    Awe 30.0% 84%
    Tactile Enhancement 29.7% 78%
    Focus Enhancement 25.8% 70%
    Introspection 22.0% 79%
    Wonder 22.0% 85%
    Sociability Enhancement 20.0% 78%
    Mystical Quality 20.0% 84%
    Fractal Imagery 20.0% 90%
    Surface Breathing 20.0% 86%
    Melting/flowing 20.0% 85%
    Insight 18.0% 84%
    Contentment 18.0% 78%
    Morphing 18.0% 86%
    Visual Trails 14.0% 81%

    Adverse Effects 44

    Anxiety 60.6% 80%
    Confusion 42.4% 81%
    Fear 18.0% 82%
    Paranoia 16.0% 78%
    Depersonalization 16.0% 79%
    Memory Suppression 15.1% 76%
    Nausea 13.0% 80%
    Panic 10.0% 81%
    Thought Disorganization 10.0% 83%
    Pupil Dilation 9.2% 82%
    Social Anxiety 8.0% 75%
    Dysphoria 8.0% 78%
    Dizziness 8.0% 75%
    Psychosis 7.4% 70%
    Muscle Tension 6.9% 90%
    Motor Impairment 6.6% 76%
    Thought Loops 6.6% 76%
    Sweating 6.2% 75%
    Tremor 6.0% 75%
    Irritability 6.0% 75%

    Dose-Response Correlation

    How effect frequency changes across dose levels

    View data table
    Effect Common (n=23) Heavy (n=17)
    Visual Distortions 82.6% 94.1%
    Music Enhancement 73.9% 47.1%
    Empathy 56.5% 29.4%
    Euphoria 56.5% 35.3%
    Confusion 56.5% 41.2%
    Anxiety 52.2% 52.9%
    Color Enhancement 52.2% 47.1%
    Stimulation 43.5% 47.1%
    Auditory Effects 26.1% 41.2%
    Tactile Enhancement 39.1% 35.3%
    Focus Enhancement 34.8% 11.8%
    Closed-Eye Visuals 30.4% 23.5%
    Introspection 30.4% 17.6%
    Memory Suppression 21.7% 29.4%
    Sedation 26.1% 17.6%

    Subjective Effect Ontology

    Experience Reports

    Structured effect tags extracted from 3,201 Erowid & Bluelight experience reports using a controlled vocabulary of 220+ canonical effects across 15 domains.

    Auditory

    music enhancement 1112 40.1% auditory distortions 601 27.4%

    Cognitive

    confusion 952 35.1% focus enhancement 566 25.8% introspection 493 23.2% memory suppression 339 13.0% creativity enhancement 169 7.7% thought loops 147 10.0%

    Emotional

    anxiety 1358 60.4% empathy 877 28.6% euphoria 828 42.6%

    Gastrointestinal

    nausea 291 12.7%

    Motor

    stimulation 868 33.7% sedation 435 14.2%

    Selfhood

    dissociation 483 15.7% ego dissolution 249 11.4%

    Somatic

    body high 242 14.8% pupil dilation 205 10.0% tension 153 7.0% sweating 140 6.8% jaw clenching 104 3.8%

    Tactile

    tactile enhancement 666 22.0%

    Temporal

    time distortion 255 8.6%

    Visual

    visual distortions 1547 57.3% color enhancement 1128 46.6% closed eye visuals 454 19.6% open eye visuals 318 14.1%

    27 unique effects extracted · Derived from Erowid & Bluelight reports

    Dose–Effect Mapping

    Experience Reports

    How reported effects shift across dose tiers, based on 2192 experience reports.

    Limited tier coverage — most reports fall within the Common / Heavy range. Effects at other dose levels may not be represented.

    Oral dose range: 100.0–250.0 µg (median 150.0 µg)
    Effect Common (n=23) Heavy (n=17)
    visual distortions
    83%
    94%
    music enhancement
    74%
    47%
    empathy
    56%
    29%
    euphoria
    56%
    35%
    confusion
    56%
    41%
    anxiety
    52%
    53%
    color enhancement
    52%
    47%
    stimulation
    44%
    47%
    auditory effects
    26%
    41%
    tactile enhancement
    39%
    35%
    focus enhancement
    35%
    12%
    closed-eye visuals
    30%
    24%
    introspection
    30%
    18%
    memory suppression
    22%
    29%
    sedation
    26%
    18%
    dissociation
    26%
    12%
    nausea
    17%
    24%
    hospital
    24%
    ego dissolution
    22%
    thought loops
    9%
    18%

    Showing top 20 of 27 effects

    Risk Escalation

    Sentiment Analysis

    Average frequency of positive vs adverse effects across dose tiers

    Common n=23
    10 positive 42.2% 8 adverse 23.4%
    Heavy n=17
    9 positive 31.4% 7 adverse 26.9%
    View effect breakdown

    Adverse Effects

    Effect Common (n=23) Heavy (n=17) Change
    Confusion
    56%
    41%
    -27%
    Anxiety
    52%
    53%
    1%
    Memory Suppression
    22%
    29%
    +35%
    Nausea
    17%
    24%
    +35%
    Thought Loops
    9%
    18%
    +102%
    Pupil Dilation
    13%
    12%
    -9%
    Motor Impairment
    9%
    12%
    +35%
    Muscle Tension
    9%
    0%

    Positive Effects

    Effect Common (n=23) Heavy (n=17) Change
    Music Enhancement
    74%
    47%
    -36%
    Empathy
    56%
    29%
    -47%
    Euphoria
    56%
    35%
    -37%
    Color Enhancement
    52%
    47%
    -9%
    Stimulation
    44%
    47%
    8%
    Tactile Enhancement
    39%
    35%
    -9%
    Focus Enhancement
    35%
    12%
    -66%
    Introspection
    30%
    18%
    -42%
    Creativity Enhancement
    17%
    12%
    -32%
    Body High
    17%
    0%

    Dosage Distribution

    Dose distribution from experience reports

    Oral

    Median: 150.0 µg IQR: 100.0–250.0 µg n=45

    Sublingual

    Median: 170.0 µg IQR: 112.0–300.0 µg n=20

    Real-World Dose Distribution

    62K Doses

    From 2519 individual dose entries

    Sublingual (n=25)

    Median: 0.15mg 25th: 0.1mg 75th: 0.25mg 90th: 0.3mg
    mg/kg median: 0.002 mg/kg 75th: 0.004

    Oral (n=112)

    Median: 0.15mg 25th: 0.1mg 75th: 0.2mg 90th: 0.3mg
    mg/kg median: 0.002 mg/kg 75th: 0.004

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Oral

    Median: 0.002 mg/kg IQR: 0.001–0.004 mg/kg n=40

    Sublingual

    Median: 0.002 mg/kg IQR: 0.002–0.004 mg/kg n=18

    Unknown

    Median: 0.002 mg/kg IQR: 0.001–0.006 mg/kg n=10

    Redose Patterns

    Redosing behavior across 1744 reports

    15.6% Redosed
    1.2 Avg Doses
    40m Median Interval

    Legal Status

    UN Convention on Psychotropic Substances 1971 (Schedule I)
    Country Status Notes
    Australia Schedule 9 Prohibited substance under the Poisons Standard. Manufacture, possession, sale, or use is prohibited except for approved medical or scientific research. Possession of under 5 doses was decriminalized in the Australian Capital Territory as of October 28, 2023.
    Austria Illegal Prohibited under the Suchtmittelgesetz (Addictive Substances Act). Possession, production, and sale are illegal.
    Belgium Illegal Prohibited without government clearance. Possession, purchase, sale, and production are all illegal.
    Brazil Controlled Listed on Portaria SVS/MS nº 344. Possession, production, and distribution are illegal.
    Canada Schedule III CDSA Controlled under the Controlled Drugs and Substances Act. Possession carries imprisonment up to 3 years. Possession for purpose of trafficking is an indictable offense punishable by up to 10 years imprisonment.
    Croatia Controlled Listed as a controlled substance under national drug legislation.
    Czech Republic Decriminalized (small amounts) Since 2010, possession of up to 5 tabs has been decriminalized. Individuals possessing less than this threshold may be charged with a misdemeanor or receive a police warning rather than criminal prosecution.
    Denmark Category A Classified as a Category A controlled substance, the most restrictive scheduling category in Danish drug law.
    Finland Controlled (hard drug) Listed in Finland's controlled substances registry in the hard-drug category.
    Germany Anlage I BtMG Controlled under Schedule I of the Betäubungsmittelgesetz (Narcotics Act) since February 25, 1967. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing are illegal without a license.
    Greece Class A Classified as a Class A drug. Possession and sale are illegal without a special government license.
    Italy Tabella I Schedule I controlled substance. Possession of less than 0.15 mg of active principle results in administrative sanctions. Higher amounts fall under penal code with imprisonment of 6 to 20 years and fines from €26,000 to €260,000.
    Japan Narcotic Classified as a narcotic under the Narcotic and Psychotropic Drugs Control Act (麻薬及び向精神薬取締法).
    Latvia Schedule I Listed as a Schedule I controlled substance under Latvian drug legislation.
    Luxembourg Prohibited Classified as a prohibited substance under national drug laws.
    Mexico Controlled (personal use decriminalized) Controlled substance, but a 2009 law decriminalized personal possession of up to 15 micrograms. This threshold is notably below the typical active dose.
    Netherlands List I (Opiumwet) Controlled under List I of the Opium Law. Possession, distribution, and production are illegal without a license. Notably, personal use itself is not criminalized.
    New Zealand Class A (Schedule I) Classified as a Class A controlled substance, the most restrictive category under New Zealand drug law.
    Norway Schedule I (Narcotic) Classified as a narcotic substance. Purchase and possession without a special license are illegal.
    Poland I-P Listed under 'Wykaz środków odurzających i substancji psychotropowych' (List of narcotic substances and psychotropic substances) in category I-P. Ownership, production, and sale are prohibited.
    Portugal Decriminalized (personal use) Decriminalized for personal use since July 2001 under Law 30/2000. Possession of less than 500 µg is not a criminal offense, though the substance may be confiscated and individuals referred to a dissuasion commission or fined. Production and sale remain criminal offenses.
    Russia List I (Список I) Controlled under List I of Russian drug legislation. Possession, production, and sale are illegal. Research may be conducted under special license.
    Sweden Schedule I (Förteckning I) Listed in Schedule I of Swedish controlled substances law, the most restrictive category.
    Switzerland Verzeichnis D Specifically listed as a controlled substance under Verzeichnis D of Swiss drug legislation. Legally approved psychiatric use continued until 1993.
    United Kingdom Class A Controlled under the Misuse of Drugs Act 1971. Possession without a license is punishable by up to 7 years imprisonment and/or an unlimited fine. Trafficking carries penalties up to life imprisonment and unlimited fines.
    United States Schedule I Controlled under Schedule I of the Controlled Substances Act of 1970. Possession was first made illegal on October 24, 1968. Manufacturing, purchasing, possession, processing, and distribution without a DEA license are prohibited. Classified as having high abuse potential with no accepted medical use.
    ← Back to LSD